Subscribe to RSS
DOI: 10.1055/s-0043-1770122
Monographic Issue on Pulmonary Hypertension: Medical and Interventional Treatment for Chronic Thromboembolic Pulmonary Hypertension
![](https://www.thieme-connect.de/media/srccm/202306/lookinside/thumbnails/10-1055-s-0043-1770122_230611-1.jpg)
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. The reasons why clots do not resorb are incompletely understood, but the result is partial or complete fibrothrombotic obstruction of pulmonary arteries. A secondary microvasculopathy aggravates the pulmonary hypertension (PH) as a consequence of high flow and shear stress in the nonoccluded arteries. The treatment of CTEPH has long been purely surgical, but many patients were inoperable because of inaccessible lesions or severe comorbidities. Alternatives were developed, including medical therapy and more recently balloon pulmonary angioplasty (BPA). Depending on the generation of the obstructed vessels, the treatment will be surgical, up to the (sub)segmental level, or by BPA for more distal vessels. PH drugs are used to treat the microvasculopathy. The current paper describes the therapeutic management of inoperable patients: the medical approach with PH drugs used in mono- or combination therapy; the proper use of anticoagulants in CTEPH; the technique, indications, and results at short- and long-term of BPA; the multimodal approach for inoperable patients combining PH drugs and BPA; and the effects of rehabilitation. It shows the importance of a multidisciplinary approach to the disease.
Note
The University Hospitals of Leuven are part of the European Reference Network for rare lung diseases (ERN-Lung).
Publication History
Article published online:
11 August 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A. et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017; 49 (02) 1601792
- 2 Valerio L, Mavromanoli AC, Barco S. et al; FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022; 43 (36) 3387-3398
- 3 Coquoz N, Weilenmann D, Stolz D. et al. Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. Eur Respir J 2018; 51 (04) 1702505
- 4 Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143) 160112
- 5 Azarian R, Wartski M, Collignon MA. et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997; 38 (06) 980-983
- 6 Humbert M, Kovacs G, Hoeper MM. et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61 (01) 2200879
- 7 Humbert M, Kovacs G, Hoeper MM. et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43 (38) 3618-3731
- 8 Pepke-Zaba J, Delcroix M, Lang I. et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124 (18) 1973-1981
- 9 Lang IM, Simonneau G, Pepke-Zaba JW. et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost 2013; 110 (01) 83-91
- 10 Bonderman D, Wilkens H, Wakounig S. et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33 (02) 325-331
- 11 Delcroix M, Torbicki A, Gopalan D. et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57 (06) 2002828
- 12 Helmersen D, Provencher S, Hirsch AM. et al. Diagnosis of chronic thromboembolic pulmonary hypertension: a Canadian Thoracic Society clinical practice guideline update. Can J Respir Critical Care Sleep Medicine [Internet] 2019; 3 (04) 177-198
- 13 Remy-Jardin M, Ryerson CJ, Schiebler ML. et al. Imaging of pulmonary hypertension in adults: a position paper from the Fleischner society. Radiology 2021; 298 (03) 531-549
- 14 Kawakami T, Ogawa A, Miyaji K. et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty. Circ Cardiovasc Interv 2016; 9 (10) e003318
- 15 Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology 1992; 182 (02) 393-398
- 16 Skoro-Sajer N, Hack N, Sadushi-Koliçi R. et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation 2009; 119 (02) 298-305
- 17 Ghofrani H-A, D'Armini AM, Grimminger F. et al; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369 (04) 319-329
- 18 Simonneau G, D'Armini AM, Ghofrani HA. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45 (05) 1293-1302
- 19 Sadushi-Koliçi R, Jansa P, Kopeć G. et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019; 7 (03) 239-248
- 20 Suntharalingam J, Treacy CM, Doughty NJ. et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134 (02) 229-236
- 21 Jaïs X, D'Armini AM, Jansa P. et al; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52 (25) 2127-2134
- 22 Delcroix M, Lang I, Pepke-Zaba J. et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133 (09) 859-871
- 23 Delcroix M, Staehler G, Gall H. et al. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. Eur Respir J 2018; 52 (05) 1800248
- 24 Guth S, D'Armini AM, Delcroix M. et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH registry. ERJ Open Res 2021; 7 (03) 00850-02020
- 25 Kerr KM, Elliott CG, Chin K. et al. Results from the United States chronic thromboembolic pulmonary hypertension registry: enrollment characteristics and 1-year follow-up. Chest 2021; 160 (05) 1822-1831
- 26 Ghofrani H-A, Simonneau G, D'Armini AM. et al; MERIT study investigators. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med 2017; 5 (10) 785-794
- 27 Galiè N, Barberà JA, Frost AE. et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
- 28 Gabrielly M, Bourlier D, Taniguchi Y. et al. Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2018; 52 (suppl 62): PA3053
- 29 van Thor MCJ, Snijder RJ, Kelder JC, Mager JJ, Post MC. Does combination therapy work in chronic thromboembolic pulmonary hypertension?. Int J Cardiol Heart Vasc 2020; 29: 100544
- 30 Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013; 41 (04) 985-990
- 31 Bunclark K, Newnham M, Chiu YD. et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020; 18 (01) 114-122
- 32 Sedhom R, Megaly M, Gupta E, Amanullah A. Use of direct oral anticoagulants in chronic thromboembolic pulmonary hypertension: a systematic review. J Thromb Thrombolysis 2022; 53 (01) 51-57
- 33 Sena S, Bulent M, Derya K. et al. Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study. Pulm Circ 2020; 10 (01) 20 45894019873545
- 34 Humbert M, Simonneau G, Pittrow D. et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022; 41 (06) 716-721
- 35 Jeong I, Alotaibi M, Fernandes TM. et al. Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy. Pulm Circ 2022; 12 (03) e12110
- 36 Frey R, Becker C, Saleh S, Unger S, van der Mey D, Mück W. Clinical pharmacokinetic and pharmacodynamic profile of riociguat. Clin Pharmacokinet 2018; 57 (06) 647-661
- 37 Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43 (15) 1089-1115
- 38 Bertoletti L, Mismetti V, Giannakoulas G. Use of anticoagulants in patients with pulmonary hypertension. Hamostaseologie 2020; 40 (03) 348-355
- 39 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
- 40 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
- 41 Khairani CD, Bejjani A, Piazza G. et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol 2023; 81 (01) 16-30
- 42 Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141 (08) 678-693
- 43 Mahmud E, Patel M, Ang L, Poch D. Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Pulm Circ 2021; 11 (02) 20 458940211007385
- 44 Minatsuki S, Kiyosue A, Kodera S. et al. Novel balloon pulmonary angioplasty technique for chronic thromboembolic pulmonary hypertension. Int Heart J 2020; 61 (05) 999-1004
- 45 Inohara T, Kawakami T, Kataoka M. et al. Lesion morphological classification by OCT to predict therapeutic efficacy after balloon pulmonary angioplasty in CTEPH. Int J Cardiol 2015; 197: 23-25
- 46 Inami T, Kataoka M, Shimura N. et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv 2013; 6 (07) 725-736
- 47 Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5 (06) 748-755
- 48 Tabuchi I, Ogawa A, Shigetoshi M, Shimokawahara H, Ito H, Matsubara H. Low incidence of restenosis after successful balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Cardiovasc Intervention Ther 2023; 38 (02) 231-240
- 49 Tatebe S, Fukumoto Y, Sugimura K. et al. Optical coherence tomography as a novel diagnostic tool for distal type chronic thromboembolic pulmonary hypertension. Circ J 2010; 74 (08) 1742-1744
- 50 Brenot P, Jaïs X, Taniguchi Y. et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53 (05) 1802095
- 51 Cannon JE, Su L, Kiely DG. et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom national cohort. Circulation 2016; 133 (18) 1761-1771
- 52 Shimokawahara H, Nagayoshi S, Ogawa A, Matsubara H. Continual improvement in pressure gradient at the lesion after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Can J Cardiol 2021; 37 (08) 1232-1239
- 53 Galiè N, Humbert M, Vachiery J-L. et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46 (04) 903-975
- 54 Galiè N, Humbert M, Vachiery J-L. et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
- 55 Darocha S, Araszkiewicz A, Kurzyna M. et al. Balloon pulmonary angioplasty in technically operable and technically inoperable chronic thromboembolic pulmonary hypertension. J Clin Med 2021; 10 (05) 1038
- 56 Darocha S, Pietura R, Banaszkiewicz M. et al. Balloon pulmonary angioplasty with stent implantation as a treatment of proximal chronic thromboembolic pulmonary hypertension. Diagnostics (Basel) 2020; 10 (06) 363
- 57 Shimura N, Kataoka M, Inami T. et al. Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2015; 183: 138-142
- 58 Araszkiewicz A, Darocha S, Pietrasik A. et al. Balloon pulmonary angioplasty for the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2019; 278: 232-237
- 59 Ito R, Yamashita J, Sasaki Y. et al. Efficacy and safety of balloon pulmonary angioplasty for residual pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol 2021; 334: 105-109
- 60 Hug KP, Gerry Coghlan J, Cannon J. et al. Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment. J Heart Lung Transplant 2021; 40 (10) 1223-1234
- 61 Godinas L, Verbelen T, Delcroix M. Residual pulmonary hypertension after pulmonary thromboendarterectomy: incidence, pathogenesis and therapeutic options. Ann Cardiothorac Surg 2021
- 62 Shimokawahara H, Ogawa A, Matsubara H. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: advances in patient and lesion selection. Curr Opin Pulm Med 2021; 27 (05) 303-310
- 63 Amsallem M, Guihaire J, Arthur Ataam J. et al. Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. J Heart Lung Transplant 2018; 37 (09) 1102-1110
- 64 Madani MM. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: state-of-the-art 2020. Pulm Circ 2021; 11 (02) 20 458940211007372
- 65 Wiedenroth CB, Olsson KM, Guth S. et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulm Circ 2018; 8 (01) 20 45893217753122
- 66 Inami T, Kataoka M, Kikuchi H, Goda A, Satoh T. Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest. Int J Cardiol 2019; 289: 116-118
- 67 Voorburg JA, Cats VM, Buis B, Bruschke AV. Balloon angioplasty in the treatment of pulmonary hypertension caused by pulmonary embolism. Chest 1988; 94 (06) 1249-1253
- 68 Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001; 103 (01) 10-13
- 69 Kataoka M, Inami T, Hayashida K. et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5 (06) 756-762
- 70 Hoole SP, Coghlan JG, Cannon JE. et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. Open Heart 2020; 7 (01) e001144
- 71 Godinas L, Bonne L, Budts W. et al. Balloon pulmonary angioplasty for the treatment of nonoperable chronic thromboembolic pulmonary hypertension: single-center experience with low initial complication rate. J Vasc Interv Radiol 2019; 30 (08) 1265-1272
- 72 Ogawa A, Satoh T, Fukuda T. et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017; 10 (11) e004029
- 73 Fukui S, Ogo T, Morita Y. et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 2014; 43 (05) 1394-1402
- 74 Broch K, Murbraech K, Ragnarsson A. et al. Echocardiographic evidence of right ventricular functional improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2016; 35 (01) 80-86
- 75 Tsugu T, Murata M, Kawakami T. et al. Significance of echocardiographic assessment for right ventricular function after balloon pulmonary angioplasty in patients with chronic thromboembolic induced pulmonary hypertension. Am J Cardiol 2015; 115 (02) 256-261
- 76 Sato H, Ota H, Sugimura K. et al. Balloon pulmonary angioplasty improves biventricular functions and pulmonary flow in chronic thromboembolic pulmonary hypertension. Circ J 2016; 80 (06) 1470-1477
- 77 Yamasaki Y, Nagao M, Abe K. et al. Balloon pulmonary angioplasty improves interventricular dyssynchrony in patients with inoperable chronic thromboembolic pulmonary hypertension: a cardiac MR imaging study. Int J Cardiovasc Imaging 2017; 33 (02) 229-239
- 78 Schoenfeld C, Hinrichs JB, Olsson KM. et al. Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. Eur Radiol 2019; 29 (04) 1693-1702
- 79 Marchetta S, Verbelen T, Claessen G, Quarck R, Delcroix M, Godinas L. A comprehensive assessment of right ventricular function in chronic thromboembolic pulmonary hypertension. J Clin Med 2022; 12 (01) 47
- 80 Fujii S, Nagayoshi S, Ogawa K. et al. A pilot cohort study assessing the feasibility of complete revascularization with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. PLoS One 2021; 16 (07) e0254770
- 81 Blanquez-Nadal M, Piliero N, Guillien A. et al. Exercise hyperventilation and pulmonary gas exchange in chronic thromboembolic pulmonary hypertension: effects of balloon pulmonary angioplasty. J Heart Lung Transplant 2022; 41 (01) 70-79
- 82 Miura K, Katsumata Y, Kawakami T. et al. Exercise tolerance and quality of life in hemodynamically partially improved patients with chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. PLoS One 2021; 16 (07) e0255180
- 83 Aoki T, Sugimura K, Tatebe S. et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. Eur Heart J 2017; 38 (42) 3152-3159
- 84 Minatsuki S, Kodera S, Kiyosue A. et al. Balloon pulmonary angioplasty improves quality of life in Japanese patients with chronic thromboembolic pulmonary hypertension. J Cardiol 2020; 76 (02) 205-210
- 85 Darocha S, Pietura R, Pietrasik A. et al. Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J 2017; 81 (04) 552-557
- 86 Taniguchi Y, Jaïs X, Jevnikar M. et al. Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2019; 38 (08) 833-842
- 87 Wiedenroth CB, Rolf A, Steinhaus K. et al. Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2023; 42 (01) 134-139
- 88 Ejiri K, Ogawa A, Fujii S, Ito H, Matsubara H. Vascular injury is a major cause of lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2018; 11 (12) e005884
- 89 Ejiri K, Ogawa A, Matsubara H. Bail-out technique for pulmonary artery rupture with a covered stent in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv 2015; 8 (05) 752-753
- 90 Lang I, Meyer BC, Ogo T. et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143) 160119
- 91 Jaïs X, Brenot P, Bouvaist H. et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 2022; 10 (10) 961-971
- 92 Grünig E, Eichstaedt C, Barberà J-A. et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J 2019; 53 (02) 1800332
- 93 Nagel C, Prange F, Guth S. et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012; 7 (07) e41603
- 94 Inagaki T, Terada J, Tanabe N. et al. Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study. Respir Investig 2014; 52 (06) 357-364
- 95 Fukui S, Ogo T, Takaki H. et al. Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Heart 2016; 102 (17) 1403-1409
- 96 Olsson KM, Wiedenroth CB, Kamp JC. et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49 (06) 1602409
- 97 Poch DS, Mahmud E, Patel M. et al. Patient selection for balloon pulmonary angioplasty: six-year results from a high volume PTE surgical center. Pulm Circ 2022; 12 (04) e12148